Synektik

Synektik S.A. Secures Major Contract for da Vinci Surgical System in Slovakia

Synektik S.A., through its subsidiary SYNEKTIK Czech Republic, s.r.o., has signed a significant agreement with the University Hospital Bratislava (Univerzitná nemocnica Bratislava) in Slovakia. The contract involves the sale, delivery, installation, and commissioning of the da Vinci robotic surgical system, along with personnel training and warranty-based service support. The deal, valued at €3,023,085.00 net, was awarded following a public procurement process under Slovak law.

The delivery and installation of the system are scheduled to be completed by May 31, 2026, with a 24-month warranty period starting from the final acceptance protocol. The agreement represents 5% of Synektik Group's equity value, as reported in its latest financial statement, and is expected to contribute to the company's revenue in FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This contract aligns with Synektik S.A.'s core business focus on distributing advanced medical technologies, including the da Vinci robotic surgical system, and reinforces its position as a leading provider of innovative healthcare solutions in Central Europe.

Synektik S.A. Reports Significant Growth in Medical Equipment Orders for FY2025

Synektik S.A., a leading Polish medical technology company, has announced a substantial increase in orders within its medical equipment, IT solutions, and services segment during the first six months of FY2025. The Group secured orders worth approximately 311 million PLN, marking a dramatic rise compared to 147 million PLN in the same period of FY2024. Notably, Q2 FY2025 orders reached 163 million PLN, a significant leap from 33 million PLN in Q2 FY2024.

As of March 31, 2026, the backlog of orders awaiting fulfillment stood at 114.3 million PLN, a sharp increase from 10.8 million PLN recorded on March 31, 2025. However, the value of active offers decreased to 165.3 million PLN from 222.4 million PLN year-over-year. The company emphasized that these figures are preliminary and subject to adjustments in its upcoming interim report.

These results underscore Synektik's growing presence in the medical technology market, aligning with its business model of providing cutting-edge medical equipment, IT solutions, and radioisotopes for diagnostic imaging.

Healthcare System Faces Leadership and Efficiency Crisis Amid Growing Pressures

The Polish healthcare system is grappling with a multifaceted crisis, including issues of financing, efficiency, and leadership, according to strategic management expert Krzysztof Zdobylak. The lack of effective leadership has hindered the resolution of systemic problems, with the National Health Fund (NFZ) criticized for implementing cost-cutting measures without adequate analysis. These measures, such as reducing reimbursement rates for certain procedures, have sparked backlash from patients, doctors, and hospitals.

Demographic, technological, and financial pressures are expected to intensify, making it imperative to adopt a dual approach: a long-term systemic transformation over three years and an immediate rescue plan focusing on efficiency. Key recommendations include improving data collection, enhancing transparency, and incentivizing healthcare providers based on performance metrics. The current system's inefficiencies, particularly in hospital financing and service delivery, highlight the need for structural reforms, including the consolidation of smaller hospitals to achieve economies of scale and improve care quality.

While Poland boasts world-class medical facilities and skilled professionals, the lack of robust quality measurement and data-driven decision-making undermines the system's overall effectiveness. The upcoming parliamentary elections are likely to delay significant reforms, as political considerations take precedence over systemic improvements.

Relevance to Synektik S.A.: The article underscores the growing importance of advanced medical technologies and data-driven solutions, areas where Synektik S.A. excels through its innovative IT platforms, diagnostic imaging systems, and robotic surgical technologies like the da Vinci system. These solutions align with the urgent need for efficiency and quality improvements in the healthcare sector.

Polish Health Minister Advocates for Optimized Healthcare Financing to Prioritize Diagnostics

Poland's Minister of Health, Jolanta Sobierańska-Grenda, has emphasized the need to restructure healthcare financing to ensure faster and more effective diagnostics for patients, particularly those with urgent needs such as oncology patients and children. In light of financial challenges faced by the National Health Fund (NFZ), the government has introduced measures such as degresive payment rates for diagnostic procedures, including CT scans, MRIs, colonoscopies, and gastroscopies, to balance costs while maintaining service availability. The minister reassured that oncology diagnostics will remain fully funded and prioritized, with 100% reimbursement for patients with DiLO cards.

Discussions are ongoing regarding further adjustments to the financing model for ambulatory specialist care, with consultations involving stakeholders and national consultants. The ministry is also exploring long-term solutions to address systemic financial shortfalls, including potential reforms to health insurance contributions. Despite record healthcare budgets, the NFZ faces a projected funding gap of 18 billion PLN by 2026, prompting the need for immediate and strategic interventions to ensure the sustainability of healthcare services.

Relevance to Synektik S.A.: The focus on improving diagnostic capabilities and prioritizing oncology patients aligns with Synektik S.A.'s expertise in advanced medical technologies, including diagnostic imaging systems and radioisotopes for PET imaging, which are critical for cancer diagnostics and treatment planning.

Poland Ordered to Fulfill COVID-19 Vaccine Contract with Pfizer, Faces Multi-Billion Zloty Penalty

The First Instance Court in Brussels has ruled that Poland must honor its agreement with American pharmaceutical giant Pfizer to purchase COVID-19 vaccines. The court ordered Poland to accept the remaining 64 million doses and pay 5.644 billion PLN, along with interest, for the unfulfilled contract. The agreement, brokered by the European Commission in 2021, obligated Poland to procure a specified number of vaccine doses. However, Poland ceased accepting deliveries in 2022, leading Pfizer to file a lawsuit in September 2023.

The court found no evidence of irregularities in the public procurement process or abuse of dominant market position by Pfizer. It also dismissed Poland's arguments that the war in Ukraine and declining infection rates justified contract termination. The ruling is not final, and Poland's Ministry of Health has announced plans to appeal, citing the need for further legal analysis regarding financial settlements and logistical aspects of vaccine delivery. A similar ruling was issued against Romania, which was ordered to pay 600 million euros for uncollected vaccines.

Relevance to Synektik S.A.: This ruling highlights the critical importance of fulfilling contractual obligations in the healthcare sector, a principle that directly impacts companies like Synektik S.A., which operates in medical technology and supplies advanced healthcare solutions under long-term agreements. Such legal precedents emphasize the need for meticulous contract management in the industry.

Poland Develops Long-Term Strategy to Boost Pharmaceutical Industry and Attract Investments

Poland is crafting a comprehensive strategy to enhance its pharmaceutical industry, focusing on fostering dialogue between the government and innovative pharmaceutical companies. According to Michał Byliniak, General Director of the Employers' Union of Innovative Pharmaceutical Companies (INFARMA), the initiative aims to align government expectations with industry needs, particularly in areas like clinical trials, investment in manufacturing facilities, and the production of active pharmaceutical ingredients (API). The strategy involves collaboration with key government bodies, including the Ministry of Health, Ministry of Finance, and Ministry of Development and Technology, to create a competitive and flexible environment for long-term investments.

Key proposals include improving the efficiency of reimbursement processes, reducing timelines for clinical trials, and removing regulatory barriers that hinder innovation. The industry also seeks government guarantees to support large-scale investments, such as building new factories and expanding production lines, which require a 15-20 year outlook. Byliniak emphasized the importance of Poland leveraging its skilled workforce, central European location, and existing capabilities in clinical research to position itself as a hub for pharmaceutical innovation. However, he noted that stronger government-industry partnerships are essential to compete with other European nations vying for similar investments.

INFARMA also highlighted the need to counter global trends, such as the U.S. "America First" policy, which has led to a reduction in the availability of new therapies in Europe. The organization stressed the urgency of creating conditions that attract cutting-edge therapies and investments to Poland, ensuring the country's pharmaceutical sector remains competitive on the global stage.

While the strategy is still in its conceptual phase, Byliniak expressed optimism about ongoing discussions with government representatives, despite challenges posed by bureaucratic silos. He called for a unified approach to address the industry's needs and secure Poland's position as a leader in pharmaceutical innovation.

Relevance to Synektik S.A.: The development of a long-term pharmaceutical strategy aligns with Synektik S.A.'s focus on innovation in medical technologies, including the production of radiopharmaceuticals and advanced diagnostic solutions, positioning the company to benefit from a more supportive and competitive industry environment in Poland.

Synektik S.A. Completes Corporate Division, Establishes Syn2bio S.A. as Independent Entity

On March 27, 2026, the District Court for the Capital City of Warsaw officially registered the division of Synektik S.A., resulting in the creation of Syn2bio S.A. as a separate entity. This division involved the transfer of a portion of Synektik's assets, including material and intangible components, liabilities, and operations related to the "Kardioznacznik" project and the Center for Research on New Molecules. These assets were classified as an organized part of the enterprise, enabling Syn2bio S.A. to focus on specific economic tasks. The remaining operations of Synektik S.A. will continue unchanged.

As part of the division, each Synektik S.A. shareholder will receive one share of Syn2bio S.A. for every share held in Synektik S.A. According to the division schedule outlined in Syn2bio S.A.'s prospectus, April 1, 2026, will mark the final trading session for Synektik S.A. shares that include the right to acquire Syn2bio S.A. shares.

This strategic move aligns with Synektik S.A.'s business model by streamlining its operations and enabling focused growth in specialized areas such as radioisotope markers and molecular research, while maintaining its core activities in medical technology and IT solutions.

Synektik S.A. Secures Major Contracts for da Vinci Surgical Systems in Gdańsk Hospitals

On March 23, 2026, Synektik S.A., a leading Polish medical technology company, announced the signing of significant agreements with COPERNICUS Podmiot Leczniczy Sp. z o.o. in Gdańsk. The contracts involve the delivery, installation, and commissioning of two da Vinci robotic surgical systems for the M. Kopernik Hospital and St. Wojciech Hospital in Gdańsk. The agreements also include staff training, warranty service, and the supply of consumables for a period of 36 months. The total net value of the contracts amounts to PLN 29,969,644.17, funded through the National Recovery and Resilience Plan. The systems are expected to be delivered within 30 days of contract signing, with a 72-month warranty period starting from the final acceptance protocol.

Relevance: This development aligns with Synektik S.A.'s business profile as the exclusive distributor of da Vinci robotic surgical systems in Poland, reinforcing its position as a leader in advanced medical technologies and minimally invasive surgical solutions.

Challenges in Poland's Healthcare System: Financial Strain and Service Limitations

The Polish healthcare system is facing significant financial challenges, as highlighted by Deputy Health Minister Tomasz Maciejewski during a parliamentary session. Despite record-high healthcare spending of over PLN 217 billion, the growth in costs has outpaced revenue increases. Key issues include the financial burden of the minimum wage law, which is projected to cost over PLN 71 billion by 2026, and a shift in funding structure, with the health insurance contribution dropping to 80% by 2025 and state budget contributions rising to PLN 33 billion in 2025.

The National Health Fund (NFZ) has proposed limiting funding for certain diagnostic tests, including colonoscopies, gastroscopies, CT scans, and MRIs, performed beyond set quotas. While these changes exclude children, adolescents, oncology patients, and those in colorectal cancer prevention programs, critics argue that the measures could lead to longer waiting times, reduced hospital liquidity, and increased reliance on private healthcare. Additionally, the closure of maternity wards continues, with 27 facilities shut down in 2025 alone, raising concerns about access to essential services.

Maciejewski assured that patient safety remains a priority and emphasized that the proposed changes aim to streamline patient pathways, particularly for oncology care. However, opposition voices have criticized the measures as a step toward healthcare privatization and a threat to public health security.

Relevance to Synektik S.A.: The financial strain and restructuring of Poland's healthcare system could impact the demand for advanced medical technologies and services, such as those provided by Synektik S.A., including diagnostic imaging systems, robotic surgical platforms, and radioisotopes for medical diagnostics.

Poles Demand Faster Access to Hospital Treatment, Highlighting Healthcare Challenges

A recent survey titled "Hospital Treatment Through the Eyes of Poles," conducted in January 2026 for LUX MED Group, reveals significant concerns among Poles regarding access to hospital care. The study found that 71% of respondents believe their health could deteriorate significantly while waiting for treatment, with 53% citing long waiting times as their primary concern. Additionally, 70% of participants stated that obtaining planned hospital treatment in Poland is challenging, with the average waiting time exceeding four months—double the acceptable duration for most respondents.

The survey also highlighted that 21% of individuals who opted out of hospital treatment did so due to prolonged waiting times, while 20% cited the need for multiple consultations and tests as a deterrent. Logistical challenges and complex procedures were also noted as barriers to accessing care. Furthermore, 48% of respondents expressed interest in private hospital insurance, which would provide faster access to advanced medical treatments and include a care coordinator to streamline the process. Notably, 68% of participants wished for such insurance to be offered as an employee benefit, with 91% desiring coverage for their family members.

The findings underscore the growing demand for alternative healthcare solutions, as public healthcare systems face challenges in meeting patient needs. The survey was conducted by ARC Rynek i Opinia Sp. z o.o. using the CAWI method, involving 1,016 working-age individuals from cities with populations exceeding 50,000.

Relevance to Synektik S.A.: The findings highlight the increasing demand for advanced medical technologies and private healthcare solutions, aligning with Synektik S.A.'s focus on providing cutting-edge medical equipment, IT solutions, and innovative treatments like robotic surgery systems and radioisotopes for diagnostics.

CEBioForum 2026: A Premier Platform for Life Science Innovation and Collaboration

CEBioForum 2026, a leading international biotechnology conference, will take place on April 22–23, 2026, in Warsaw, Poland. For over 20 years, this event has served as a hub for connecting the life science communities of Central and Eastern Europe with the United States. The forum will bring together key stakeholders, including biotechnology and pharmaceutical leaders, medtech representatives, investors, scientists, and business support institutions, to discuss innovation commercialization, project financing, strategic partnerships, and the future of the sector, particularly the rapidly growing #polishbiotech.

The event offers numerous business opportunities, including:

• CEBioForum Awards: Recognizing the most innovative projects and companies in the region, enhancing their credibility and international visibility.
• Biotech Pitch Session: A platform for presenting projects to investors, venture capital funds, and industry partners.
• B2B Matchmaking App: Facilitating one-on-one meetings and efficient agenda planning to maximize networking value.
• Expert Panels and Keynote Speeches: Covering regulatory, investment, and technological trends in pharma, medtech, biotech, clinical trials, and data analysis.
• Access to Decision-Makers: A unique opportunity to meet key representatives of the Polish and regional life science ecosystem.

CEBioForum is organized by BioForum, an association of nearly 50 life science companies, which fosters collaboration between science and business, initiates acceleration projects, and promotes international partnerships. The event is a flagship initiative aimed at advancing the biotechnology sector in Poland and beyond.

Learn more about CEBioForum 2026

Relevance to Synektik S.A.: As a leader in medtech and a key player in the Polish life sciences sector, Synektik S.A. stands to benefit from the networking, partnership, and innovation opportunities offered by CEBioForum 2026, aligning with its focus on advanced medical technologies and strategic collaborations.

Synektik S.A. Secures Major Contract for Robotic Surgery System Delivery to Gdańsk University Clinical Center

Synektik S.A., a leading Polish medical technology company, has signed significant agreements with the University Clinical Center in Gdańsk for the delivery, installation, and commissioning of the fifth-generation da Vinci robotic surgery system. The contracts also include staff training, warranty-period service support, and the supply of consumables over a 48-month period. The total net value of the agreements amounts to PLN 21,201,352.31, funded by the National Recovery and Resilience Plan.

The project, awarded through an open public tender, is set for completion by May 30, 2026, with a 48-month warranty period starting from the final acceptance protocol. The agreements are considered crucial by Synektik's management, as their value exceeds 5% of the company’s equity, as reported in its latest financial statement. Revenue from this project is expected to positively impact Synektik’s financial results for fiscal years 2025-2027.

Relevance: This development aligns with Synektik S.A.'s business profile as a key distributor of advanced medical technologies, including robotic surgery systems, and underscores its leadership in delivering cutting-edge healthcare solutions in Poland.

Poland Considers Adopting Canadian Strategy to Address Men's Health Disparities

Poland is exploring the adaptation of Canada's "Men and Boys’ Health Strategy" to address significant health disparities between men and women. The Canadian initiative, launched in February, focuses on mental health, combating harmful social stereotypes, and improving early detection and prevention of common health issues, including cancer. Polish lawmakers, led by MP Marcin Józefaciuk, have highlighted the urgent need for a similar systemic approach, citing alarming statistics such as high suicide rates among men and inadequate access to preventive healthcare services.

Healthcare professionals in Poland have pointed out gaps in the system, such as limited diagnostic tools available to general practitioners and insufficient early screening for young males. Experts also emphasized the importance of educating men about self-examinations and addressing mental health challenges, particularly in rural areas where health risks are more pronounced. The National Health Fund (NFZ) has initiated campaigns to raise awareness, including outreach during sports events and partnerships with rural organizations. A preliminary draft of Poland's men's health strategy, tailored to local needs, is expected in May.

Additionally, workplace safety disparities were highlighted, with men accounting for 96% of fatal workplace accidents in 2024. Experts called for stronger public campaigns to promote health awareness and mental well-being, alongside free psychological support for men facing challenges such as divorce-related conflicts.

Relevance to Synektik S.A.: The focus on early cancer detection and preventive healthcare aligns with Synektik S.A.'s expertise in advanced medical technologies, including diagnostic imaging systems and radioisotopes for PET scans, which are critical for early diagnosis and treatment planning.

e-DiLO Implementation Delayed Until 2029, Aiming to Revolutionize Oncology Care

The long-awaited implementation of the electronic Diagnostic and Treatment Card for Oncology (e-DiLO) has been postponed to 2029, despite earlier promises of its rollout in 2025. The e-DiLO system, designed to streamline the diagnostic and therapeutic pathways for oncology patients, remains hindered by legislative delays, including the need for amendments to the National Oncology Network (KSO) Act. The system aims to replace the current paper-based DiLO cards, offering centralized access to patient data, diagnostic plans, treatment schedules, and integration with histopathology systems. This digital transformation is expected to enhance data sharing across medical facilities and improve patient care coordination.

In 2025, over 440,000 DiLO cards were issued, reflecting a steady increase in usage compared to previous years. However, the current paper-based system remains tied to specific medical facilities, creating inefficiencies for patients who switch hospitals or experience disease recurrence. The Ministry of Health has acknowledged the potential of e-DiLO to accelerate diagnostics and specialist consultations but emphasized that its integration with the national e-registration system will take several more years to materialize. For now, patients are advised to continue using the paper-based system for registration and referrals.

Experts, including Prof. Piotr Rutkowski and Prof. Jacek Jassem, have highlighted the transformative potential of e-DiLO in oncology care, emphasizing its ability to provide real-time updates on patient health and ensure continuity of care across facilities. However, the lack of legislative foresight in the original KSO Act has significantly delayed its implementation, leaving patients and healthcare providers to navigate the limitations of the current system.

Relevance to Synektik S.A.: The e-DiLO system aligns with Synektik S.A.'s focus on advanced IT solutions for healthcare, such as its PACS imaging systems and Zbadani.pl platform, showcasing the company's potential role in supporting the digital transformation of oncology care in Poland.

Synektik S.A. Announces Strategic Division of Assets into SYN2BIO S.A.

On March 18, 2026, Synektik S.A., a leading Polish medical technology company, will hold an Extraordinary General Meeting to discuss the division of the company’s assets. The proposed plan involves transferring a portion of Synektik’s assets to a newly established entity, SYN2BIO S.A. This strategic move aims to streamline operations and enhance the company’s focus on its core business areas, including the production of radiopharmaceuticals, distribution of advanced medical equipment, and development of healthcare IT solutions.

Synektik S.A. is renowned for its exclusive distribution of the da Vinci robotic surgery systems, production of PET radiopharmaceuticals, and innovative medical software solutions. The creation of SYN2BIO S.A. is expected to further strengthen the company’s position in the medical technology sector by enabling more specialized operations and fostering growth in targeted areas.

The decision to restructure reflects Synektik’s commitment to maintaining its leadership in the Polish healthcare market and adapting to evolving industry demands.

Relevance: This development aligns with Synektik S.A.’s business model of optimizing its operations across medical technology, radiopharmaceuticals, and IT solutions, ensuring sustained growth and innovation in its core sectors.

Key Events on the NewConnect Market Calendar for March 2026

The NewConnect market has announced a series of extraordinary general meetings scheduled for March 2026, involving several companies. These meetings will address critical corporate matters such as changes in supervisory boards, capital increases, and statutory amendments. Notable events include:

• March 18: FIGENE continues its extraordinary general meeting from February 16.
• March 19: GKSKAT, NOVINA, and UNIFIED will hold meetings to discuss changes in supervisory boards, share issuance, and remuneration policies.
• March 20: DEMGAMES plans to discuss a merger with Quest Craft SA, capital increases, and statutory changes, while AQUAPOZ will address supervisory board appointments.
• March 23: SWMANSION will hold a meeting to appoint new supervisory board members.

These developments reflect ongoing corporate governance adjustments and strategic decisions across the NewConnect market.

Relevance to Synektik S.A.: Monitoring corporate activities on the NewConnect market is crucial for Synektik S.A., as it operates in a competitive and dynamic environment where strategic decisions, such as capital increases or governance changes, can influence market trends and opportunities.

Key Economic Events Scheduled for March 18-24, 2026

The upcoming week is set to feature several significant economic and business events in Poland and beyond, with a focus on energy security, financial performance, and market challenges. Highlights include the PowerConnect Energy Summit 2026, a two-day forum starting on March 18, addressing energy transformation in the Baltic region and the development of domestic supply chains. The event will bring together government officials, energy company executives, and technology leaders.

Additionally, multiple companies will host financial results conferences, including CD Projekt on March 19, Żabka and Sanok Rubber Company on March 20, and Torpol on March 23. These sessions will provide insights into their 2025 performance and strategic plans for 2026. Other notable events include the NWAI press conference on March 18, focusing on operational and financial summaries, and the GUS conference on March 24, discussing the role of statistics in business decision-making.

These events reflect the dynamic economic landscape and the growing emphasis on innovation, sustainability, and financial transparency across industries.

Relevance to Synektik S.A.: The focus on technological innovation and strategic planning aligns with Synektik S.A.'s role as a leader in advanced medical technologies and IT solutions, emphasizing its position in a competitive and evolving market.

Challenges in Polish Healthcare System Reform Highlighted During Health Challenges Congress

Experts at the Health Challenges Congress (HCC) debated the ongoing challenges in reforming Poland's hospital system, expressing concerns over the lack of a clear and actionable plan to address patient needs. Waldemar Malinowski, President of the National Association of County Hospital Employers, criticized the absence of a comprehensive reform strategy and called for guaranteed funding for newly passed legislation. Bernadeta Skóbel from the Association of Polish Counties highlighted the uncertainty surrounding hospital restructuring due to unclear financial frameworks and changing reimbursement policies.

Filip Nowak, President of the National Health Fund (NFZ), emphasized the need for hospitals to base restructuring plans on demographic analyses and financial sustainability, while also addressing the issue of degressive payments for services exceeding contractual limits. Renata Wachowicz, Director of UCK SUM in Katowice, pointed out the financial strain caused by reduced reimbursement rates for over-limit procedures, such as vitrectomy. Meanwhile, Barbara Więckowska from the Ministry of Health stressed the need to adapt hospital infrastructure to modern treatment methods, such as day surgeries enabled by technological advancements.

The Ministry of Health announced plans to create a roadmap for hospital service provision, with a national transformation plan expected by the end of 2025. The recently signed legislation aims to rationalize and increase the flexibility of hospital services, encouraging the consolidation of acute care services and the transition to planned or one-day treatments where feasible. Financial incentives are also proposed to support these transformations.

Relevance to Synektik S.A.: The article underscores the growing importance of advanced medical technologies and IT solutions in modernizing healthcare systems, aligning with Synektik S.A.'s expertise in providing cutting-edge medical equipment, robotic surgical systems, and IT platforms for healthcare optimization.

Poland to Revamp Drug Policy with Focus on Domestic Production and Technological Advancements

Poland is set to introduce a new "State Drug Policy for 2026–2030," aiming for a comprehensive overhaul of the pharmaceutical sector. The strategy, announced by Deputy Health Minister Katarzyna Kacperczyk during the Health Challenges Congress, will emphasize a holistic approach to the sector, including reforms to the reimbursement law and the role of the Agency for Health Technology Assessment and Tariff System (AOTMiT). The government plans to allocate 31 billion PLN for drug reimbursement, while also redefining institutional roles and improving funding mechanisms.

A key focus of the policy is strengthening Poland's drug security by boosting domestic production. Industry leaders, including Barbara Misiewicz-Jagielak of Polpharma and Ewa Królikowska of Teva Pharmaceuticals Polska, highlighted the importance of local manufacturing to enhance resilience. However, they acknowledged the long-term nature of such investments, which require 15–20 years to materialize. Additionally, the strategy will prioritize the integration of advanced technologies, such as artificial intelligence, to accelerate drug research and support reimbursement decisions.

Dr. Anna Kowalczuk, the new president of the Medical Research Agency, advocated for simplified drug administration schemes and underscored the transformative potential of AI in the pharmaceutical industry. The overarching goal of the policy is to position Poland as a reliable partner for pharmaceutical companies while ensuring sustainable and efficient healthcare solutions for its citizens.

Relevance to Synektik S.A.: The emphasis on domestic production, advanced medical technologies, and AI-driven healthcare aligns with Synektik S.A.'s expertise in medical technology, IT solutions, and radioisotope production, presenting potential opportunities for collaboration and growth in the evolving Polish healthcare landscape.

Healthcare Industry Experts Question the Impact of Conferences and Panels

Dr. Anna Gołębicka, a business strategist and member of the National Health Fund Council, has raised critical questions about the effectiveness of the numerous healthcare conferences and panels held in recent years. In a recent discussion, she likened the healthcare sector to a hierarchical and complex "court of Louis XIV," where discussions often fail to translate into actionable changes. Dr. Gołębicka highlighted the prevalence of repetitive narratives from panelists and the growing fatigue among participants, as attendance at such events appears to be declining. Despite this, she acknowledged the importance of these gatherings for networking and staying informed about rapid changes in healthcare policies and market dynamics. She emphasized the unique challenges of the healthcare sector, including its complexity, hierarchical structure, and constant evolution of regulations and financial constraints.

Relevance to Synektik S.A.: As a leading provider of advanced medical technologies and IT solutions, Synektik S.A. operates in the highly dynamic healthcare sector. Staying informed about industry trends and regulatory changes discussed in such forums is crucial for maintaining its competitive edge and adapting to market needs.

Challenges in Public Healthcare Financing Drive Demand for Private Insurance

Experts warn that the financial gap in Poland's public healthcare system is widening, prompting renewed discussions about the introduction of supplementary health insurance. The guaranteed benefits package, established in 2009 under the so-called "basket law," has been criticized for its inefficiencies and lack of precise definitions for medical technologies and treatments. Despite increased healthcare funding over the past decade, medical inflation and mismanagement have hindered access to services, leaving many patients waiting an average of 4.2 months for treatment, according to the Watch Health Care Foundation.

Private health insurance is gaining popularity, with 5.39 million Poles now covered, a 12% increase from the previous year. These policies primarily focus on faster access to diagnostic and specialist care, particularly in oncology, ophthalmology, and cardiology. Experts argue that a more clearly defined benefits package and the development of complementary insurance could alleviate pressure on the public system. Additionally, there is a growing call for the introduction of long-term care insurance to address the rising costs of elder care.

Relevance to Synektik S.A.: The article highlights the increasing demand for advanced medical technologies and private healthcare solutions, aligning with Synektik S.A.'s role as a leading provider of cutting-edge medical equipment, IT solutions, and radioisotopes for diagnostics, as well as its exclusive distribution of the da Vinci robotic surgery system in Poland.

Polish Entrepreneurs Call for Reform in Drug Reimbursement Processes Amid Financial Strain

The Federation of Polish Entrepreneurs (FPP) has urged the Minister of Health to address significant delays in drug reimbursement processes caused by current regulations. The issue stems from a 2023 amendment to the reimbursement law, which mandates the termination of reimbursement proceedings after 12 months if pharmacoeconomic analyses (HTA) expire. This has led to the suspension of therapies, even those supported by scientific evidence and expert recommendations, due to the financial challenges faced by the National Health Fund (NFZ).

The FPP has proposed several measures, including the suspension of reimbursement proceedings for new therapies and indications until the NFZ's financial stability improves, as well as the removal of time limits on HTA validity in the ongoing legislative process. The Ministry of Health plans to introduce a draft amendment to the reimbursement law in the second quarter of this year to address these concerns.

Relevance to Synektik S.A.: The article is relevant to Synektik S.A. as the company operates in the medical technology and radiopharmaceutical sectors, where reimbursement policies directly impact the adoption and accessibility of innovative therapies and technologies, including their advanced diagnostic and surgical solutions.

Synektik S.A. Secures Major Contract for da Vinci Surgical System Installation

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the Regional Specialist Hospital named after Dr. Władysław Biegański in Grudziądz. The contract, valued at PLN 12,884,425.54 net, involves the delivery, installation, and commissioning of the da Vinci robotic surgical system, along with adaptation works, personnel training, and warranty-period service support. The agreement was finalized following a public procurement process conducted through an open tender.

The delivery and installation of the da Vinci system are expected to be completed within 40 days of signing the contract, with a warranty period of 60 months starting from the final acceptance protocol. The deal represents 5% of Synektik Group's equity as reported in its latest financial statement, meeting the company's internal reporting standards for significant agreements. Revenue from this project will contribute to the financial results of FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This agreement underscores Synektik S.A.'s position as the exclusive distributor of the da Vinci robotic surgical system in Poland and highlights its role in advancing minimally invasive surgical technologies in the healthcare sector.

Robotic Surgery Revolutionizes Gynecological Procedures in Poland

Robotic surgery is transforming gynecological procedures in Poland, offering groundbreaking advancements in treating complex conditions such as deep infiltrating endometriosis, myomectomy, and early-stage ovarian cancer. Dr. Daniel Kurczyński from the Katowice Oncology Center highlights the significant benefits of robotic systems, particularly the da Vinci surgical platform, in enhancing surgical precision, reducing patient recovery time, and minimizing complications compared to traditional laparoscopic or open surgeries.

One of the key drivers of robotic surgery adoption in gynecology has been the increased reimbursement for endometrial cancer surgeries over the past 2.5 years. These procedures, which are standardized and relatively straightforward, have allowed hospitals to treat a larger number of patients with improved outcomes. Robotic systems provide superior visualization, ergonomic advantages for surgeons, and reduced trauma to tissues, leading to faster recovery and lower postoperative pain for patients. Additionally, robotic surgery is particularly advantageous for obese patients and those with complex anatomical challenges, such as multi-organ adhesions caused by endometriosis.

Dr. Kurczyński emphasizes the need for quality control and data collection in robotic surgery to ensure consistent outcomes and foster continuous improvement. He advocates for the use of surgical recordings and clinical registries to analyze and enhance surgical techniques, as well as to provide transparency for patients and healthcare providers. Furthermore, he underscores the importance of training younger surgeons in robotic systems to maximize the long-term benefits of this advanced technology.

Robotic surgery is also paving the way for innovative procedures, such as scar defect repair after cesarean sections and urogynaecological surgeries. However, challenges remain, including the higher costs associated with robotic systems and the need for better reimbursement models for complex procedures like endometriosis surgeries. Despite these hurdles, robotic surgery is poised to play a pivotal role in advancing gynecological care in Poland.

Relevance to Synektik S.A.: This article highlights the growing adoption and benefits of the da Vinci robotic surgical system, which Synektik S.A. exclusively distributes in Poland. It underscores the company's role in advancing medical technology and improving patient outcomes through innovative solutions.

Edge Medical Expands Robotic Surgery Market in Poland and Central Europe

Edge Medical, a Chinese manufacturer of surgical robots, has rapidly expanded its presence in Poland and Central Europe, achieving significant milestones in robotic surgery. Since receiving European certification in mid-2025, the company has installed five MP1000 multi-port robotic systems in Polish hospitals, including facilities in Kościerzyna, Mielec, Rzeszów, and Częstochowa. The company plans to introduce its single-port SP1000 system, which received European certification in late 2025, to Polish hospitals in 2026. The SP1000 system is designed for specialized procedures in urology, gynecology, thoracic surgery, and other fields, offering advanced technology at competitive costs.

Edge Medical has also established a robust training infrastructure, including a center in Otwock in collaboration with CMKP and another planned facility in Częstochowa. These centers aim to train surgeons in robotic systems, ensuring a smooth transition to advanced surgical technologies. Additionally, Edge Medical has pioneered tele-surgery in Poland, enabling remote operations and expanding the possibilities of robotic-assisted procedures. The company is also building a distribution network across eight Central European countries, including the Baltics, Czech Republic, and Romania, with plans for further installations and partnerships in 2026.

Despite growing competition in the Polish market, the da Vinci system remains the dominant player. However, Edge Medical is positioning itself as a strong competitor by offering cost-effective solutions, longer-lasting tools, and innovative technologies. The company’s focus on affordability, training, and technological advancements is expected to drive further adoption of robotic surgery in the region.

Relevance to Synektik S.A.: This article highlights the competitive landscape of the robotic surgery market in Poland, where Synektik S.A. is the exclusive distributor of the da Vinci surgical system. The emergence of Edge Medical as a competitor underscores the importance of Synektik's continued innovation and strategic positioning in the growing field of robotic-assisted surgery.

Hypertension: A Silent Epidemic Threatening Public Health

Hypertension, often referred to as the "silent killer," affects over 11 million Poles, making it a national health crisis. Despite the availability of effective and affordable medications, the disease remains poorly managed due to a lack of awareness, non-compliance with medical advice, and neglect of regular blood pressure monitoring. Experts emphasize that untreated hypertension is a leading cause of heart attacks, strokes, kidney failure, and premature deaths. Early detection, lifestyle changes, and adherence to prescribed therapies are critical to reversing this alarming trend.

Specialists advocate for systematic blood pressure screenings starting from childhood, as studies show that hypertension affects up to 5% of children and adolescents. Public health initiatives, such as the "Mission 50/30" campaign by the Polish Society of Hypertension, aim to ensure that by 2030, half of all hypertension patients achieve therapeutic goals. However, achieving this requires a collaborative effort between healthcare providers and patients, emphasizing education, regular monitoring, and adherence to treatment plans.

Lowering systolic blood pressure by just 10 mmHg can significantly reduce the risk of complications, including a 27% decrease in stroke risk and a 13% reduction in overall mortality. With consistent efforts, experts remain optimistic about improving outcomes and extending the lifespan of those affected by this chronic condition.

Relevance to Synektik S.A.: This article highlights the importance of advanced medical technologies and solutions, such as diagnostic imaging systems and IT platforms like those provided by Synektik S.A., in addressing public health challenges like hypertension through early detection and effective management.

Synektik S.A. Expands Robotic Surgery Portfolio and Strengthens Market Leadership

Synektik S.A., a leading Polish medical technology company, continues to solidify its position as a pioneer in robotic surgery solutions. By the end of 2025, the company had successfully installed 83 authorized da Vinci surgical systems in Polish hospitals, with an additional 38 installations across the Baltic states, Czech Republic, Slovakia, and Ukraine. In 2025 alone, Synektik completed 27 new installations and introduced the advanced da Vinci 5 model and Symani robots for microsurgery to the market. The company is also preparing to launch the single-port da Vinci SP system and the Ion robotic bronchoscopy system in 2026.

To address diverse hospital needs, Synektik offers a wide range of robotic systems, including refurbished da Vinci XiR models, which come with full warranties and service support. This initiative aligns with the company’s commitment to sustainability and affordability. Despite growing competition, particularly from Chinese manufacturers, Synektik emphasizes the superior quality, reliability, and cost-effectiveness of its systems, supported by Intuitive Surgical’s extensive R&D investments and global expertise.

Synektik’s efforts extend beyond sales, with a strong focus on training and support. The company has trained over 380 surgical teams in Poland and plans to open a new training center in Warsaw in collaboration with SGGW in 2026. Additionally, Synektik is driving the adoption of robotic systems in emerging fields such as pediatric surgery, head and neck surgery, and thoracic surgery, while continuing to enhance its offerings with advanced digital and AI functionalities.

Recognized as the "Distributor of the Year" in 2025 for its excellence in training, implementation, and service, Synektik remains committed to advancing robotic surgery and improving patient outcomes. With over 20 million da Vinci procedures performed globally and a robust support system, the company is well-positioned to maintain its leadership in the rapidly evolving medical robotics market.

Relevance to Synektik S.A.: This article highlights Synektik’s strategic initiatives, product portfolio expansion, and market leadership in robotic surgery, directly aligning with its core business model of providing cutting-edge medical technologies and solutions to healthcare providers.

Synektik S.A. Announces Extraordinary General Meeting to Discuss Strategic Division

Synektik S.A., a leading Polish medical technology company, has scheduled an Extraordinary General Meeting (EGM) of Shareholders for March 19, 2026, at its headquarters in Warsaw. The meeting will address key corporate matters, including the proposed division of the company. The division involves transferring a portion of Synektik's assets to a newly established entity, SYN2BIO S.A., as part of a strategic restructuring plan.

The proposed division will see the transfer of a segment of Synektik's business, specifically related to the production of cardiomarkers and CBNC, to SYN2BIO S.A. This move is aimed at optimizing operations and focusing on core business areas. Shareholders of Synektik S.A. will receive shares in SYN2BIO S.A. in a 1:1 ratio, ensuring their proportional ownership in the new entity. The division will not affect Synektik's share capital, and the new shares will be listed on the Warsaw Stock Exchange.

The Supervisory Board of Synektik S.A. has positively endorsed the proposed resolutions, which will be presented for approval during the EGM. The company has also provided detailed procedural guidelines for shareholders to participate in the meeting and exercise their voting rights.

Relevance to Synektik S.A.: This development aligns with Synektik S.A.'s strategic focus on enhancing its operational efficiency and expanding its presence in the medical technology sector, particularly in the production of advanced diagnostic solutions.

Synektik S.A. Announces Planned Division and Asset Transfer to Syn2bio S.A.

Synektik S.A., a leading Polish medical technology company, has announced its intention to divide the company and transfer part of its assets to Syn2bio S.A., based in Warsaw. The division will involve the transfer of an organized part of Synektik's enterprise, specifically assets related to the "Kardioznacznik" and "CBNC" projects, to Syn2bio S.A. The process will be conducted in accordance with Article 529 § 1 point 4 of the Polish Commercial Companies Code (KSH).

The division plan, including all relevant documentation and an auditor's opinion, has been made publicly available on the websites of both companies and will remain accessible until the conclusion of the general meetings of both entities, where the division resolution will be adopted. The transfer will include both material and non-material assets, which are financially and organizationally distinct within Synektik's operations.

The division is part of Synektik's strategic efforts to streamline its operations and focus on its core business areas, including the production of radiopharmaceuticals, distribution of advanced medical equipment, and IT solutions for healthcare.

Relevance: This development aligns with Synektik S.A.'s business model, as it reflects the company's strategy to optimize its operations and focus on its key segments, including radiopharmaceuticals and advanced medical technologies.

Synektik S.A. Projects Growth in EBITDA and Expands Presence in New Markets

Synektik S.A., a leading Polish medical technology company, anticipates continued growth in normalized EBITDA and an increase in recurring revenues, according to Vice President Dariusz Korecki. The company plans to introduce its flagship da Vinci robotic surgical systems to the Baltic countries this year, marking a significant expansion into new markets. Additionally, Synektik expects the impact of its sales in Ukraine to become evident in the next financial year, signaling further international growth opportunities.

These developments align with Synektik's business strategy of expanding its footprint in the medical technology sector, particularly through the distribution of advanced robotic surgical systems and the provision of innovative healthcare solutions.

National Health Fund: A Key Element in Poland's Healthcare System

Dr. Piotr Bromber, a political scientist and economist, emphasizes the importance of the National Health Fund (NFZ) as a cornerstone of Poland's healthcare system in his latest book, "Narodowy Fundusz Zdrowia w systemie ochrony zdrowia. Pacjenci – Ekonomia – Polityka." With over 20 years of operation, NFZ is described as a valuable asset rather than a burden, playing a crucial role in financing healthcare services and addressing systemic challenges. Bromber highlights the need for strategic planning, improved patient satisfaction, and stable regulations to enhance NFZ's effectiveness.

While acknowledging criticisms, Bromber argues that NFZ's perceived shortcomings often stem from issues with healthcare providers rather than the fund itself. He advocates for a balanced approach that considers the perspectives of various stakeholders, including patients, policymakers, and healthcare providers. Recommendations include fostering trust, enhancing service quality, and refining the relationship between NFZ and the Ministry of Health to ensure long-term stability and efficiency.

Relevance to Synektik S.A.: The article underscores the importance of strategic healthcare financing and patient-centered approaches, aligning with Synektik S.A.'s focus on delivering advanced medical technologies and solutions that improve healthcare outcomes in Poland.

MedTech Solutions Signs Letter of Intent for Strategic Acquisition in Orthopedics and Surgery

MedTech Solutions has announced the signing of a letter of intent to acquire 100% of shares in a distribution company specializing in orthopedics and surgery. The target company, which operates in over 100 hospitals, reported a net profit of approximately PLN 1 million in 2025. The acquisition aims to strengthen MedTech Solutions' market position and lay the groundwork for further consolidation in the medical device sector.

The deal includes a term sheet expected to be finalized within 30 days, outlining key transaction parameters. The acquired company boasts a specialized four-person sales team and a portfolio of over 100 active distribution contracts with Polish hospitals, covering medical products in orthopedics and surgery. MedTech Solutions plans to integrate sales structures and leverage product synergies to optimize operational efficiency and enhance commercial effectiveness.

This acquisition marks the first step in building a larger distribution platform in the medical device segment. The process will involve due diligence and negotiation of transaction documentation, with completion contingent on meeting standard legal and formal requirements.

MedTech Solutions is listed on the NewConnect market.

Relevance to Synektik S.A.: The acquisition aligns with Synektik S.A.'s focus on distributing advanced medical technologies and solutions, highlighting the competitive landscape and opportunities for growth in the Polish healthcare market.

Challenges and Opportunities in Poland's Healthcare Pilot Programs

Poland's healthcare system is grappling with the prolonged implementation of pilot programs, initially designed as short-term projects to test and refine innovative solutions. Among the most notable is the pilot for Mental Health Centers (CZP), which has been extended multiple times since its inception in 2018 and is now set to run until the end of 2026. This program aims to provide comprehensive local support for individuals facing mental health crises, transitioning from institutional to community-based care. Despite its success in reaching hundreds of thousands of patients annually, scaling the model to cover the entire population remains a significant challenge.

Other pilot programs, such as trauma therapy, coordinated care for neurofibromatosis patients, and initiatives promoting physical activity, have also faced delays and extensions. Key barriers include legislative gaps, incomplete evaluations by the Agency for Health Technology Assessment and Tariff System (AOTMiT), and disruptions caused by the COVID-19 pandemic. Experts highlight the need for better project management and clearer end-goals to ensure these pilots transition into permanent, well-funded services.

Technological advancements, such as telemonitoring for heart failure patients and centralized e-registration systems, are also being tested, showcasing the potential for digital solutions to enhance healthcare delivery. However, scaling these innovations across hundreds of facilities remains a complex task.

The relevance of this article to Synektik S.A. lies in the company's role as a provider of advanced medical technologies and IT solutions, which could support the implementation and scaling of innovative healthcare models, including telemedicine and diagnostic systems.

Innovaris Expands Distribution of Versius Plus Surgical Robots in Poland

Innovaris, a subsidiary of Anmar Group, has announced plans to expand the distribution and installation of Versius Plus surgical robots in Poland. The advanced robotic system, developed by CMR Surgical, is recognized for its high level of digitalization, integration of artificial intelligence, and modular design, making it a future-oriented solution for minimally invasive surgeries. Currently, 11 Versius systems are operational in 10 Polish hospitals, with new installations planned in the coming months. The system's compact design and advanced features, such as fluorescence imaging and enhanced energy tools, have proven effective in complex procedures, including pediatric surgeries and reconstructive operations.

Innovaris emphasizes the importance of data-driven insights, enabling real-time monitoring and optimization during surgeries. The company also highlights the system's efficiency, with faster preparation times and reduced interoperative delays, making it a cost-effective choice for hospitals. Innovaris aims to focus on expanding its presence in general surgery, thoracic surgery, pediatrics, urology, and gynecology, while addressing the growing demand for alternatives to existing robotic systems.

Globally, Versius Plus has achieved over 250 installations and 40,000 procedures, with Poland emerging as a key market alongside countries like the UK, Italy, and India. Innovaris is committed to supporting hospitals in leveraging the system's capabilities to improve surgical outcomes and operational efficiency.

Relevance to Synektik S.A.: The article highlights the growing adoption of advanced surgical robotics in Poland, a market where Synektik S.A. plays a significant role as the exclusive distributor of the da Vinci robotic system. This development underscores the competitive landscape and the increasing demand for innovative medical technologies, aligning with Synektik's focus on cutting-edge healthcare solutions.

Synektik S.A. Announces Planned Division of Assets to Syn2bio S.A.

Synektik S.A., a leading Polish medical technology company, has announced its intention to divide its assets and transfer a portion to Syn2bio S.A., a Warsaw-based entity. The division will involve the transfer of an organized part of Synektik's enterprise, including material and immaterial assets related to the "Kardioznacznik" and "CBNC" projects. This process will be conducted in accordance with Article 529 § 1 point 4 of the Polish Commercial Companies Code (KSH).

The division plan, which outlines the terms and conditions of the transfer, was made publicly available on July 23, 2025, on the websites of both Synektik S.A. (Synektik Investor Center) and Syn2bio S.A. (Syn2bio). Supporting documents, including the auditor's opinion, are accessible online and at the headquarters of both companies until the conclusion of their respective general meetings, where the division will be formally approved.

The transfer aims to streamline Synektik's operations by focusing on its core business areas while enabling Syn2bio to develop the transferred projects further.

Relevance: This development aligns with Synektik S.A.'s strategic focus on innovation and specialization in medical technologies, particularly in the production of radiopharmaceuticals and advanced healthcare solutions.

Synektik Expands Distribution of da Vinci Surgical Robots to Ukraine

Synektik S.A., a leading Polish medical technology company, has announced the expansion of its exclusive distribution agreement with Intuitive Surgical to include Ukraine. The collaboration, which now spans Poland, Czechia, Slovakia, Lithuania, Latvia, Estonia, and Ukraine, has also been extended until the end of 2031. This move aligns with Synektik's strategy to enhance the availability of advanced surgical technologies in Central and Eastern Europe.

Under the agreement, Synektik will provide the Ukrainian market with da Vinci robotic surgical systems, offering comprehensive support including sales, implementation, training, service infrastructure development, and regulatory and marketing assistance. By the end of 2025, Synektik had 83 da Vinci systems operating in Poland and a total of 121 across the region.

Synektik's CEO, Cezary Kozanecki, emphasized the company's commitment to expanding access to cutting-edge surgical solutions, stating that the new agreement provides a solid foundation for further growth in the region.

Relevance: This development highlights Synektik's strategic focus on expanding its footprint in the robotic surgery market, a key segment of its business model, and reinforces its position as a leader in distributing advanced medical technologies in Central and Eastern Europe.

Synektik Secures Contract with Świętokrzyskie Oncology Center for da Vinci Surgical System

Synektik S.A., a leading Polish medical technology company, has announced the signing of a contract with the Świętokrzyskie Oncology Center in Kielce for the delivery, installation, and commissioning of the da Vinci robotic surgical system. The deal is valued at PLN 18.3 million net. This advanced system will enhance the center's capabilities in performing minimally invasive surgeries with greater precision and control.

The agreement underscores Synektik's position as the exclusive distributor of Intuitive Surgical's da Vinci systems in Poland and highlights its commitment to providing cutting-edge medical technologies to healthcare institutions.

Breakthrough in Autonomous Robotic Surgery Achieved by MicroPort MedBot

Chinese medical robotics company MicroPort MedBot has announced a significant breakthrough in autonomous robotic surgery with the successful completion of an experimental procedure on animal models. Utilizing its advanced AI-driven surgical system, MicroGenius, the company demonstrated the ability to autonomously perform key stages of soft tissue surgery, including bile duct clamping and cutting, with an 88% success rate in a single attempt. The system also showcased real-time dynamic adjustments during the procedure, completing the entire surgery autonomously.

The MicroGenius model, powered by approximately 3 billion parameters, operates on a two-layer AI architecture. The higher layer, trained on 23,000 surgical video records, enables advanced understanding of the surgical field and procedure planning. The lower layer, trained on over 10,000 surgical samples, ensures precise robotic arm movements and stable operation. A novel training paradigm combining small-scale in vivo data with large-scale ex vivo data was employed, significantly reducing reliance on costly in vivo datasets. Additionally, the model demonstrated adaptability across various robotic systems, marking a milestone in the development of autonomous surgical algorithms.

This achievement represents a paradigm shift in robotic surgery, moving from rule-based automation to a holistic, AI-driven autonomous approach. MicroPort MedBot's innovation could pave the way for more precise, efficient, and accessible surgical solutions globally.

Relevance to Synektik S.A.: This development highlights advancements in robotic surgery, a field where Synektik S.A. is a key player as the exclusive distributor of the da Vinci surgical system in Poland. The progress in autonomous surgical systems underscores the importance of innovation in medical robotics, aligning with Synektik's focus on cutting-edge healthcare technologies.

Major Healthcare Reforms in Poland: Digitalization, New Medical Documentation Standards, and Changes to Sick Leave Policies

Poland is set to undergo significant healthcare reforms starting January 2026, with a focus on digitalization, improved patient services, and updated medical documentation standards. Key changes include the introduction of the Central e-Registration system, which will streamline appointment scheduling for patients through online platforms, mobile apps, and voice assistants. Initially available for cardiology and cancer prevention programs, the system will expand to cover all medical services by 2029. Healthcare facilities will face penalties for failing to integrate with the system.

Additionally, new regulations will mandate the use of electronic medical documentation (EDM) for emergency medical teams, including digital forms for rescue operations. This aims to enhance data security, improve patient care, and eliminate paper-based processes. Changes to medical documentation will also include standardized referral formats and digital storage requirements, improving the efficiency and accuracy of healthcare data exchange.

In occupational medicine, electronic medical certificates will be introduced, accessible via the Internet Patient Account (IKP). These certificates will include personalized health recommendations for employees, though employers will not have access to this data. Furthermore, significant updates to sick leave policies will allow nurses and physiotherapists to issue medical leave under specific conditions, while also enabling employees to work for one employer while on leave from another, provided it aligns with recovery goals.

Lastly, home rehabilitation services will be limited to 20% of ambulatory care time starting in 2026, with new billing rules for physiotherapy services to follow in April of the same year.

Relevance to Synektik S.A.: These reforms align with Synektik S.A.'s focus on healthcare IT solutions, such as its PACS imaging systems and Zbadani.pl platform, which could play a critical role in supporting the digital transformation of Poland's healthcare system.

Synektik S.A. Secures Major Contract for da Vinci Surgical System Delivery

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the University Clinical Hospital No. 2 PUM in Szczecin. The contract, valued at a net amount of PLN 18,514,000, involves the delivery, installation, and commissioning of the da Vinci robotic surgical system, along with staff training and warranty-period service support. The project will be financed through the National Recovery and Resilience Plan and is set to be completed within 60 days of the agreement's signing. The system will come with a 36-month warranty from the final acceptance protocol date.

The agreement was finalized following a public procurement process and is considered a key milestone for Synektik S.A., as its value exceeds 5% of the Group's equity, as reported in the latest financial statement. Revenue from this project will contribute to the company's financial results for FY2025, spanning October 1, 2025, to September 30, 2026.

Relevance: This contract aligns with Synektik S.A.'s core business focus on distributing advanced medical technologies, including the da Vinci robotic surgical system, and reinforces its position as a leader in the Polish healthcare technology market.

Synektik S.A. Announces Adjustments to Resolutions from Annual General Meeting

On January 21, 2026, Synektik S.A., a leading Polish medical technology company, issued a correction to its previous report (No. 7/2026) regarding resolutions adopted during the Ordinary General Meeting (OGM) held on January 20, 2026. The correction addressed a clerical error in the number of valid votes cast for resolutions numbered 01/2026 to 10/2026, 12/2026, and 14/2026 to 17/2026. The correct figure is 4,759,046 valid votes, instead of the previously reported 4,759,946.

The OGM approved several key resolutions, including:

• Approval of the financial statements for FY2024, showing a net profit of PLN 91.9 million and consolidated net profit of PLN 102.9 million.
• Allocation of PLN 91.7 million for dividend distribution, equating to PLN 10.75 per share, with the dividend payout scheduled for February 2, 2026.
• Granting discharge to the Management Board and Supervisory Board members for their duties during FY2024.
• Approval of the Supervisory Board's report and the remuneration report for 2024.

The resolutions reflect Synektik's strong financial performance and commitment to shareholder value through dividend payouts. The company continues to solidify its position as a leader in medical technology, including the production of radiopharmaceuticals and distribution of advanced medical equipment such as the da Vinci surgical systems.

Relevance: This announcement highlights Synektik S.A.'s robust financial health and strategic focus on delivering value to shareholders, aligning with its business model of innovation in medical technology and healthcare solutions.

Key Shareholders of Synektik S.A. Announced Following General Meeting

On January 20, 2026, Synektik S.A., a leading Polish medical technology company, disclosed the list of shareholders holding at least 5% of total voting rights during the Ordinary General Meeting of Shareholders. The announcement highlights the significant stakeholders in the company, reflecting its ownership structure and strategic backing.

• MELHUS COMPANY LTD: 2,047,380 votes, representing 24.00% of total voting rights and 43.02% of votes at the meeting.
• KSIĄŻEK HOLDING SP. O.O.: 1,376,143 votes, representing 16.13% of total voting rights and 28.92% of votes at the meeting.
• Funds Managed by Nationale Nederlanden PTE SA: 764,923 votes, representing 8.97% of total voting rights and 16.07% of votes at the meeting.
• Government of Norway: 331,694 votes, representing 3.89% of total voting rights and 6.97% of votes at the meeting.

This announcement underscores the strong institutional and international interest in Synektik S.A., a company renowned for its leadership in medical technologies, including robotic surgery systems, radiopharmaceuticals, and IT solutions for healthcare.

Synektik S.A. Announces Dividend Payout for FY2024

On January 20, 2026, the Ordinary General Meeting of Shareholders of Synektik S.A. approved a resolution regarding the allocation of the company’s net profit for the fiscal year from October 1, 2024, to September 30, 2025. The net profit, amounting to PLN 91,938,937.50, will be distributed as follows:

• PLN 91,688,136.75 (99.7% of the net profit) will be allocated for dividend payments, equating to PLN 10.75 per share.
• PLN 250,800.75 will be transferred to the company’s reserve capital.

The shareholders also set the dividend record date as January 29, 2026, and the dividend payment date as February 2, 2026.

This announcement underscores Synektik S.A.'s strong financial performance and commitment to delivering value to its shareholders, aligning with its position as a leader in the medical technology and radioisotope production sectors.

Synektik S.A. Shareholders Approve Key Resolutions at Annual General Meeting

On January 20, 2026, Synektik S.A., a leading Polish medical technology company, held its Annual General Meeting (AGM) in Warsaw, where shareholders approved a series of critical resolutions. The meeting covered financial performance, dividend distribution, and governance matters, reflecting the company's robust operational and financial health.

Key resolutions included:

• Approval of the financial statements for the fiscal year ending September 30, 2025, which reported a net profit of PLN 91.9 million and total assets of PLN 345.7 million.
• Approval of the consolidated financial statements of the Synektik Group, showing a net profit of PLN 102.9 million and total assets of PLN 489.1 million.
• Allocation of 99.7% of the net profit (PLN 91.7 million) for dividend distribution, resulting in a dividend of PLN 10.75 per share, with the payout scheduled for February 2, 2026.
• Granting discharge to the Management Board and Supervisory Board members for their duties during the fiscal year.
• Positive opinion on the remuneration report for 2024, confirming compliance with corporate governance standards.

The AGM also confirmed the company's commitment to transparency and shareholder value by approving the Supervisory Board's report, which included evaluations of internal control systems and risk management processes.

Relevance: The resolutions align with Synektik S.A.'s business profile as a leader in medical technology and innovation, showcasing its financial stability, governance practices, and dedication to shareholder returns.

Synektik S.A. Publishes 2024 Executive and Supervisory Board Remuneration Report

On January 16, 2026, Synektik S.A., a leading Polish medical technology company, released its comprehensive report on the remuneration of its Management Board and Supervisory Board members for the fiscal year 2024. The report, prepared in compliance with the company’s remuneration policy and Polish public company regulations, outlines the total compensation received by board members, including fixed and variable components, as well as additional benefits such as medical care and vehicle allowances.

The report highlights that the remuneration structure is designed to align with Synektik’s long-term business strategy, ensuring stability, financial performance, and alignment with shareholder interests. For 2024, CEO Cezary Kozanecki received a total remuneration of PLN 3.09 million, with 65% comprising variable components tied to company performance. Vice President Dariusz Korecki earned PLN 1.85 million, with 63% of his compensation being performance-based. Supervisory Board members received fixed remuneration only, with no variable or additional benefits.

The report also includes an independent auditor’s assessment, confirming the completeness and compliance of the remuneration disclosures with applicable regulations. The auditor emphasized that the remuneration policy effectively supports Synektik’s strategic goals and ensures transparency in corporate governance.

Additionally, the report provides a five-year comparison of company performance, board remuneration, and average employee salaries, showcasing a 19% year-over-year increase in net profit for 2024, reaching PLN 91.94 million. This growth reflects the company’s robust financial health and its commitment to rewarding performance-driven leadership.

The full report and auditor’s opinion are available on Synektik’s official website.

Relevance: This article is relevant to Synektik S.A.’s business profile as it demonstrates the company’s commitment to aligning executive compensation with its strategic objectives, financial performance, and corporate governance standards, which are critical for its leadership in the medical technology sector.

Synektik S.A. Subsidiary Secures Major Contract for da Vinci Surgical System in Czech Republic

Synektik S.A., through its subsidiary SYNEKTIK Czech Republic, s.r.o., has signed a significant agreement with the Municipal Hospital in Ostrava, Czech Republic. The contract involves the sale, delivery, installation, and commissioning of the da Vinci robotic surgical system, along with staff training and warranty-based service support. The deal, valued at $3,044,856.01 net, was finalized following a public procurement process in compliance with Czech law.

The delivery of the system is expected within 180 days of the hospital's formal request, with a 24-month warranty period commencing upon the final acceptance of the system. The agreement is considered a key milestone for Synektik S.A., as its value exceeds 5% of the Group's equity, as reported in the latest financial statements. Revenue from this project will contribute to the company's financial results for FY2025, spanning October 1, 2025, to September 30, 2026.

Relevance: This contract underscores Synektik S.A.'s leadership in distributing advanced medical technologies, particularly the da Vinci surgical system, and aligns with its strategic focus on expanding its presence in the medical equipment and IT solutions market.

Synektik S.A. Reports Strong Growth in Medical Equipment Orders in Q1 FY2025

Synektik S.A., a leading Polish medical technology company, has announced a significant increase in orders within its medical equipment, IT solutions, and services segment for the first quarter of the 2025 fiscal year. The Group secured orders worth approximately 148 million PLN, a notable rise compared to 114 million PLN in the same period of FY2024. Additionally, the backlog of orders awaiting execution as of December 31, 2025, reached 73.2 million PLN, a substantial increase from 4.3 million PLN on December 31, 2024. The value of active offers also grew to 165.9 million PLN, up from 123.4 million PLN in the previous year.

The company emphasized that these figures are preliminary estimates and may vary in the final results, which will be disclosed in the interim report for the period from October 1, 2025, to December 31, 2025.

Relevance: This growth highlights Synektik S.A.'s expanding role in the medical technology market, aligning with its business model of providing cutting-edge medical equipment, IT solutions, and services to healthcare institutions.

Synektik S.A. Secures Major Contract for da Vinci Surgical System Delivery

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the Provincial Specialist Hospital named after Blessed Father Jerzy Popiełuszko in Włocławek. The contract, valued at a net amount of PLN 13,069,826.74, involves the delivery, installation, and commissioning of the da Vinci robotic surgical system, along with staff training and warranty-period service support. The project will be financed through the National Recovery and Resilience Plan.

The delivery of the robotic system is scheduled to be completed within four weeks of the contract signing, with a warranty period of 60 months from the final acceptance protocol. The agreement was finalized following a public procurement process and is considered significant as its value exceeds 5% of Synektik Group's equity, as reported in the latest financial statement. Revenue from this project will contribute to the company's financial results for FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This contract aligns with Synektik S.A.'s core business focus on distributing advanced medical technologies, including the da Vinci robotic surgical system, and reinforces its position as a leader in the Polish healthcare technology market.

Synektik S.A. Secures Exclusive Distribution Agreement for Edison Histotripsy Systems

On January 8, 2026, Synektik S.A. announced the signing of an exclusive distribution agreement with HistoSonics Inc., a U.S.-based company specializing in advanced medical technologies. Under the agreement, Synektik will become the sole distributor of HistoSonics' Edison histotripsy systems in Poland, Czech Republic, Slovakia, Lithuania, Latvia, and Estonia. The agreement spans three years, with an option for automatic renewal for an additional two years.

The Edison system employs cutting-edge histotripsy technology, a non-invasive, non-thermal, and non-ionizing method for mechanically destroying both inoperable and resectable liver tumors. This innovative platform uses pulsed ultrasound energy to liquefy tumors at the subcellular level, with the remnants naturally absorbed by the body. The procedure is monitored in real-time using advanced imaging technologies, ensuring precision and effectiveness.

As part of the agreement, Synektik will oversee sales, servicing, consumables distribution, training, regulatory compliance, and marketing for the Edison systems in the designated regions. The partnership aligns with Synektik's strategic focus on expanding its portfolio of advanced therapeutic solutions, which is expected to significantly impact the company's financial performance.

Relevance: This agreement underscores Synektik's commitment to enhancing its position as a leader in advanced medical technologies, complementing its existing expertise in medical equipment distribution, radioisotopes production, and IT solutions for healthcare.

Synektik S.A. Announces Ordinary General Meeting of Shareholders for January 2026

Synektik S.A., a leading Polish medical technology company, has officially announced the convening of its Ordinary General Meeting of Shareholders, scheduled for January 20, 2026, at 12:00 PM. The meeting will take place at the company's headquarters in Warsaw, located at Józefa Piusa Dziekońskiego 3. The agenda includes key resolutions such as the approval of financial statements for the fiscal year ending September 30, 2025, the allocation of profits, and the distribution of dividends.

Among the significant items on the agenda are:

• Approval of the management board's report on the company's and the group's activities for FY2024.
• Approval of the standalone and consolidated financial statements for FY2024.
• Discussion and approval of the Supervisory Board's report and the remuneration report for 2024.
• Decisions on profit distribution, including a proposed dividend of PLN 10.75 per share.
• Granting discharge to members of the management and supervisory boards for their duties during FY2024.

Shareholders are encouraged to participate either in person or through authorized representatives. The company has provided detailed procedures for participation, including the submission of relevant documentation and the use of electronic communication for certain processes. The record date for participation is January 4, 2026, and shareholders must request a certificate of entitlement by January 5, 2026.

Further details, including the full agenda, draft resolutions, and procedural guidelines, are available on Synektik S.A.'s official website at https://synektik.com.pl/centrum-inwestora/walne-zgromadzenia/.

Relevance: This announcement is directly tied to Synektik S.A.'s business operations and governance, as it involves critical decisions on financial performance, profit allocation, and strategic oversight, which are essential for the company's stakeholders and future growth.

Synektik S.A. Proposes Dividend Payout of PLN 10.75 Per Share for FY2024

On December 22, 2025, the Management Board of Synektik S.A. announced its recommendation to the Ordinary General Meeting regarding the allocation of the company's net profit for the fiscal year 2024, which ended on September 30, 2025. The Board proposed allocating PLN 91,688,136.75, representing 99.7% of the company's net profit, for dividend distribution, equating to PLN 10.75 per share. The remaining profit will be added to the company's reserve capital.

The Board also recommended setting January 29, 2026, as the dividend record date and February 2, 2026, as the dividend payment date. The final decision on the profit allocation and dividend payout will be made by the Ordinary General Meeting.

Relevance: This announcement highlights Synektik S.A.'s strong financial performance and commitment to shareholder value, aligning with its position as a leading player in the medical technology and radioisotope production sectors.

Key Figures Shaping Poland's Healthcare System in 2023

As 2023 comes to a close, Poland's healthcare system reflects the contributions of numerous influential figures who have driven innovation, reform, and progress across various sectors. From advancements in medical technologies to systemic improvements, these leaders have left a significant mark on the industry.

Among the notable achievements, the integration of robotic surgery systems, such as the da Vinci platform, has revolutionized surgical precision and patient outcomes. Leaders like Cezary Kazanecki have played a pivotal role in expanding access to these technologies, with Synektik S.A. emerging as a key player in their distribution. The company has successfully supported hospitals in leveraging EU funds to adopt cutting-edge solutions, ensuring better healthcare delivery.

Additionally, figures like Piotr Suwalski have championed telechirurgical innovations, enabling remote robotic surgeries that enhance accessibility and efficiency. This aligns with Synektik's focus on advanced medical technologies and IT solutions, including imaging systems and platforms like Zbadani.pl.

Other leaders have emphasized the importance of coordinated care, data-driven strategies, and systemic reforms, which resonate with Synektik's commitment to improving healthcare infrastructure through IT solutions and long-term service agreements.

As Poland's healthcare system continues to evolve, the contributions of these individuals underscore the importance of collaboration, innovation, and strategic investments in medical technologies.

Relevance to Synektik S.A.: The article highlights advancements in robotic surgery and healthcare IT solutions, areas where Synektik S.A. plays a leading role as a distributor and innovator in Poland's medical technology landscape.

First Robotic Surgeries with da Vinci 5 System Performed in Poland at Medicover Hospital

Warsaw’s Medicover Hospital has successfully conducted Poland's first surgeries using the advanced da Vinci 5 robotic system. Among the procedures performed were radical pancreatic resections and tumor removals, led by Professor Marek Durlik and his surgical team. The da Vinci 5 system enhances surgical precision by providing high-resolution 3D imaging and advanced maneuverability tools, enabling minimally invasive operations with greater accuracy and control.

The introduction of this cutting-edge robotic technology marks a significant step in expanding Medicover Hospital's surgical capabilities. Since 2018, the hospital has been a leader in robotic surgeries in Poland, completing over 2,500 procedures. Anna Nipanicz, Director of Medicover Hospital, emphasized the transformative impact of robotic surgery on modern medicine, highlighting its role in improving treatment precision, patient safety, and overall care quality.

Medicover Hospital’s adoption of the da Vinci 5 system aligns with its commitment to technological advancement and innovation in healthcare.

Relevance to Synektik S.A.: As the exclusive distributor of the da Vinci robotic systems in Poland, Synektik S.A. plays a pivotal role in advancing robotic surgery in the country, showcasing its leadership in providing cutting-edge medical technologies.

Surge in Robotic Surgery in Poland: 2024 Report Highlights Growth and Challenges

The Modern Healthcare Institute has released a comprehensive report detailing the rapid growth of robotic-assisted surgeries in Poland during 2024. The report reveals that 17,100 robotic surgeries were performed, marking a 70% increase compared to 2023. Among these, 88% utilized the da Vinci system, while Versius accounted for 12%, and the newly introduced Hugo system performed seven procedures. Urology dominated the field, with prostatectomies making up 61% of all robotic surgeries, followed by operations for kidney and bladder cancer. Gynaecological and colorectal surgeries also saw significant adoption of robotic systems.

Despite the growth, disparities in access remain evident, with the number of robotic surgeries per thousand cancer cases varying widely across regions. The report also highlights the financial implications, noting that the National Health Fund (NFZ) spent an incremental 82.1 million PLN on robotic surgery reimbursements compared to laparoscopic procedures. Efforts to reduce the cost gap between robotic and traditional surgeries are ongoing, with NFZ adjusting reimbursement rates.

Leading hospitals in robotic surgery include the Oncology Center in Bydgoszcz, UROVITA in Chorzów, and the Military Medical Institute in Warsaw. These institutions performed hundreds of procedures across various specialties, showcasing the versatility of robotic systems. Additionally, 19 new hospitals adopted robotic surgery in 2024, contributing to the growing network of 77 facilities utilizing robotic systems in Poland.

Robotic systems are also expanding into orthopedics and neurosurgery, with advancements in spine stabilization, brain surgeries, and joint replacements. The orthopedic sector has seen the introduction of new robotic systems, such as Velys and SkyWalker, further diversifying the market.

This report underscores the transformative impact of robotic surgery on healthcare in Poland, highlighting both its potential and challenges in achieving equitable access and cost efficiency.

Relevance to Synektik S.A.: As the exclusive distributor of the da Vinci robotic surgical system in Poland, Synektik S.A. plays a pivotal role in the expansion of robotic surgery, aligning with its mission to deliver cutting-edge medical technologies and solutions to healthcare providers.

Synektik S.A. Completes Installation of da Vinci Surgical System for Private Medical Facility

Synektik S.A., a leading Polish medical technology company, has successfully completed the delivery, installation, and commissioning of the da Vinci robotic surgical system for a private medical facility. The agreement also includes personnel training and comprehensive service support during the 24-month warranty period. While the contract value remains confidential, the deal is significant as it exceeds 5% of the Group's equity, as reported in the latest financial statement. Revenue from this project will contribute to Synektik's financial results for the fiscal year 2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This development aligns with Synektik S.A.'s core business focus on distributing advanced medical technologies, including the da Vinci surgical system, and underscores its leadership in the Polish healthcare market.

Synektik Secures Multi-Million Contract with University Clinical Hospital in Poznań

Synektik S.A., a leading Polish medical technology company, has announced the signing of a significant agreement with the University Clinical Hospital in Poznań. The contract, valued at up to PLN 14.95 million net, ensures the ongoing supply of consumables for the da Vinci robotic surgical system, which is designed for minimally invasive procedures. This partnership underscores Synektik's commitment to supporting advanced medical technologies in healthcare institutions across Poland.

The agreement highlights Synektik's strategic focus on providing cutting-edge surgical solutions and long-term service support, aligning with its role as the exclusive distributor of the da Vinci robotic system in Poland.

Synektik S.A. Secures Multi-Million Contract with University Clinical Hospital in Poznań

Synektik S.A., a leading Polish medical technology company, has signed agreements with the University Clinical Hospital in Poznań for the supply of consumables for the da Vinci robotic surgical system. The contracts, awarded through an open tender process, have a total maximum net value of PLN 14,952,586.94 and will span a period of 36 months. The agreements adhere to standard terms for such contracts and are considered significant as their value exceeds 5% of Synektik Group's equity, as reported in the latest financial statement. Revenue from these contracts is expected to positively impact the company’s financial results for fiscal years 2025-2028.

This development aligns with Synektik S.A.'s business profile as a key distributor of advanced medical technologies, including the da Vinci robotic surgical system, and underscores its role in supporting minimally invasive surgical solutions in Poland.

Polish Surgeons' Society and Medtronic Launch RasCo Program to Advance Robotic Surgery in Poland

The Polish Surgeons' Society (TChP) has partnered with Medtronic Poland to establish RasCo Poland, a comprehensive educational program aimed at advancing and standardizing robotic-assisted surgery (RAS) in Poland. The initiative includes a detailed training curriculum combining theoretical lessons and practical workshops at Medtronic's Warsaw training center. The program is designed to enhance the quality and safety of robotic surgeries, particularly in oncology and general surgery, with plans to expand into gynecology and other specialties. The collaboration also involves webinars, proctoring, and expert-led sessions to ensure surgeons gain proficiency in robotic techniques. This partnership marks a significant step toward professionalizing robotic surgery in Poland, improving patient outcomes, and increasing access to advanced surgical technologies.

Relevance to Synektik S.A.: The development of robotic surgery in Poland aligns with Synektik S.A.'s role as a leading distributor of the da Vinci robotic surgical system, highlighting the growing demand for robotic-assisted surgical solutions and training in the country.

Synektik S.A. Secures Key Contracts for Robotic Surgery Systems

Synektik S.A., a leading Polish medical technology company, has announced the signing of three significant contracts in December 2025, further solidifying its position in the healthcare sector. The agreements involve the delivery, installation, and servicing of advanced robotic surgery systems, including the da Vinci and Symani platforms, to prominent medical institutions in Poland.

• On December 3, 2025, Synektik signed a contract with the 5th Military Clinical Hospital in Kraków for the supply and installation of the Symani robotic system for micro- and supermicrosurgery. The deal, valued at PLN 10.88 million net, includes staff training and warranty services.
• On December 4, 2025, the company finalized a PLN 15.73 million net agreement with the State Medical Institute of the Ministry of Internal Affairs and Administration in Warsaw for the delivery of a da Vinci robotic system, with a 36-month warranty period.
• On December 5, 2025, Synektik secured a two-year contract worth PLN 13.81 million net with the 4th Military Clinical Hospital in Wrocław for the supply of consumables for the da Vinci robotic system.

These contracts highlight Synektik's commitment to advancing minimally invasive surgical technologies and its leadership in the distribution and servicing of robotic systems in Poland.

Relevance to Synektik S.A.: These developments align with Synektik's core business model, which focuses on the distribution of cutting-edge medical technologies, including robotic surgery systems, and underscores its role as a key player in the Polish healthcare market.

Synektik S.A. Secures Major Agreement with 4th Military Clinical Hospital in Wrocław

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the 4th Military Clinical Hospital with Polyclinic SPZOZ in Wrocław. The contract, valued at a maximum net amount of PLN 13,806,915.40, pertains to the supply of consumable materials for the da Vinci robotic surgical system used by the hospital. The agreement spans a period of 24 months and adheres to standard contractual practices for such arrangements.

The deal is considered substantial by Synektik's management, as its value exceeds 5% of the Group's equity as reported in the latest financial statement. Revenues generated from this project are expected to positively impact the company's sales performance during the fiscal years 2025-2027.

Relevance: This agreement underscores Synektik's position as a key distributor of advanced medical technologies, particularly the da Vinci robotic surgical system, aligning with its strategic focus on medical equipment and consumables.

Synektik S.A. Secures Major Contract for Robotic Surgery System Delivery to MSWiA Medical Institute

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the State Medical Institute of the Ministry of Internal Affairs and Administration (MSWiA) in Warsaw. The contract, valued at PLN 15,735,000.00 net, involves the delivery, installation, and commissioning of the da Vinci robotic surgery system, along with necessary equipment, personnel training, and warranty-period service support. The system is scheduled for delivery by December 12, 2025, with a 36-month warranty starting from the final acceptance protocol signing.

The agreement was awarded through a public procurement process and is considered material due to its value exceeding 5% of Synektik Group's equity, as reported in the latest periodic financial statement. Revenue from this contract will contribute to the company's financial results for FY2025, spanning October 1, 2025, to September 30, 2026.

Relevance: This contract aligns with Synektik S.A.'s core business of distributing advanced medical technologies, particularly the da Vinci robotic surgery system, reinforcing its position as a leader in the Polish healthcare technology market.

Synektik S.A. Secures Major Contract for Robotic Surgery System Delivery

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the 5th Military Clinical Hospital with Polyclinic SPZOZ in Kraków. The contract, valued at PLN 10,879,535.44 net, involves the delivery, installation, and commissioning of the Symani robotic surgery system for micro- and supermicrosurgery. Additionally, the agreement includes staff training and service support during a 36-month warranty period. The system is scheduled for delivery by December 10, 2025, following a public procurement process.

The deal is notable as its value represents nearly 5% of Synektik Group's equity, as reported in the latest financial statement. The revenue generated from this project will contribute to the company's financial results for FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This agreement aligns with Synektik S.A.'s core business of providing advanced medical technologies, including robotic surgery systems, and reinforces its position as a key player in the healthcare technology sector.

Synektik S.A. Reports Robust Financial Growth and Strategic Developments in FY2024

Synektik S.A., a leading Polish medical technology company, has reported significant financial growth and strategic advancements for the fiscal year ending September 30, 2025. The company achieved total revenues of PLN 681.3 million, marking a 9% year-on-year increase. Key drivers included a 46% rise in sales of medical equipment and IT solutions, alongside a 12% growth in the radiofarmaceutical segment. EBITDA from continuing operations surged by 24% to PLN 177.1 million, with profitability improving to 26% from 22.9% in the previous year.

In the medical equipment segment, Synektik delivered 27 da Vinci robotic systems across Poland, Czechia, and Slovakia, bringing the total number of systems under its service to 113. The company also expanded recurring revenue streams, which grew by 60% year-on-year to PLN 311 million, driven by increased utilization of robotic systems and related services. Additionally, Synektik advanced its IT solutions, including the Zbadani.pl platform, which facilitates secure digital management of medical imaging data.

In the radiofarmaceutical segment, Synektik maintained steady growth, with revenues reaching PLN 50.5 million. The company also signed a licensing agreement with NUCLEO for the production and distribution of Glunektik in Latvia and Estonia, further strengthening its international presence.

Strategically, Synektik progressed its innovative cardiomarker project, conducting clinical trials in Europe and preparing for trials in the United States. The company also initiated a corporate restructuring to spin off its research and development activities into a new entity, Syn2bio S.A., to focus on pharmaceutical innovation and cardiomarker development.

Synektik's strong financial performance and strategic initiatives underscore its commitment to advancing medical technology and expanding its market presence.

Relevance: This article highlights Synektik S.A.'s core business areas, including medical equipment, IT solutions, and radiofarmaceuticals, while showcasing its strategic focus on innovation and international expansion, aligning with its business profile.

Synektik S.A. Announces Spin-Off of Syn2bio to Advance Cardiotracer Research and Commercialization

Synektik S.A., a leading Polish medical technology company, has announced plans to spin off its research division into a newly formed entity, Syn2bio. The company has submitted a prospectus to the Polish Financial Supervision Authority (KNF) in preparation for the issuance of Syn2bio's shares, which will be allocated to Synektik shareholders on a 1:1 basis. Both companies will be listed on the Warsaw Stock Exchange, with the division expected to be finalized by mid-2026.

Syn2bio will focus on advancing research and commercialization of Synektik's flagship cardiotracer project, an innovative radioisotope-based pharmaceutical designed for myocardial perfusion imaging and coronary artery disease diagnostics. The cardiotracer, protected by patents in key markets such as Europe and Japan, is undergoing the final phase of clinical trials, with registration processes planned for Europe and the United States upon successful completion. Synektik has already invested PLN 50 million to support Syn2bio's operations for 12-14 months post-prospectus approval.

The cardiotracer project holds significant global potential, particularly in the U.S., where approximately 7 million myocardial perfusion studies are conducted annually, and in Europe. Syn2bio aims to generate revenue through licensing agreements and direct production of the cardiotracer.

Synektik's remaining operations, including its production of radiopharmaceuticals, distribution of advanced medical equipment, and IT solutions for healthcare, will continue under the parent company.

Relevance: This development aligns with Synektik's strategic focus on innovation in radiopharmaceuticals and its commitment to expanding its global footprint in medical technology.

Synektik S.A. Secures Major Contract for da Vinci Surgical System Delivery

On October 27, 2025, Synektik S.A., a leading Polish medical technology company, announced the signing of a significant contract with the Provincial Hospital in Bielsko-Biała. The agreement, valued at PLN 12,320,891.91 net, involves the delivery, installation, and commissioning of the da Vinci robotic surgical system, along with necessary equipment, personnel training, and warranty-period servicing. The contract was awarded through an open public tender, and the delivery is expected to be completed within 90 days of signing.

This development underscores Synektik S.A.'s position as the exclusive distributor of the da Vinci robotic surgical systems in Poland and highlights its commitment to advancing minimally invasive surgical technologies in the healthcare sector.

Synektik S.A. Secures Major Contract for Robotic Surgery System Delivery to Bielsko-Biała Hospital

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the Provincial Hospital in Bielsko-Biała for the delivery, installation, and commissioning of the da Vinci robotic surgery system. The contract, valued at PLN 12,320,891.91 net, also includes staff training and comprehensive service support during the 60-month warranty period. The project will be financed through the National Recovery and Resilience Plan, with the system set to be delivered within 90 days of the agreement's signing.

The deal was finalized following a public procurement process and is considered a key milestone for Synektik S.A., as its value exceeds 5% of the company’s equity, as reported in its latest financial statement. The revenue from this project will contribute to the company’s financial results for FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This agreement underscores Synektik S.A.'s leadership in the distribution of advanced medical technologies, particularly the da Vinci robotic surgery system, aligning with its core business focus on innovative healthcare solutions and strengthening its market position in Poland.

Synektik S.A. Secures Major Contracts for Robotic Surgery Systems

Synektik S.A., a leading Polish medical technology company, has announced the signing of several significant contracts between October 20 and October 23, 2025, for the delivery and installation of advanced robotic surgery systems. These agreements highlight the company's growing presence in the healthcare sector and its commitment to providing cutting-edge medical solutions.

• October 20, 2025: Synektik signed a contract with the Provincial Hospital Complex in Elbląg for the supply, installation, and training related to the da Vinci robotic surgery system and the APOTECAchemo system for cytostatic drug preparation. The contract is valued at PLN 15,492,111.11 net.
• October 21, 2025: The company finalized an agreement with Szpitale Pomorskie Sp. z o.o. in Gdynia for the delivery and installation of the da Vinci robotic surgery system at the Specialist Hospital in Wejherowo. The contract is worth PLN 9,251,585.51 net.
• October 23, 2025: Synektik secured a deal with the Oncology Center in Poznań for the installation of the fifth-generation da Vinci robotic surgery system. The contract value is PLN 16,180,000.00 net.

Each contract includes comprehensive services such as equipment installation, personnel training, and warranty-period maintenance, ensuring seamless integration into the respective healthcare facilities.

Relevance to Synektik S.A. Profile: These contracts reinforce Synektik's position as a leader in robotic surgery systems and advanced medical technologies, aligning with its core business model of delivering innovative healthcare solutions.

Synektik S.A. Secures Major Contract for da Vinci 5 Surgical System with Wielkopolskie Centrum Onkologii

Synektik S.A., a leading Polish medical technology company, has announced the signing of a significant agreement with Wielkopolskie Centrum Onkologii in Poznań. The contract, valued at PLN 16,180,000.00 net, involves the delivery, installation, and commissioning of the fifth-generation da Vinci 5 robotic surgical system, along with necessary equipment, staff training, and warranty-period service support.

The agreement was finalized following a public procurement process and stipulates that the system will be delivered within 10 weeks of signing. The warranty period for the system extends to 36 months from the final acceptance protocol. The deal is considered a key milestone for Synektik S.A., as its value exceeds 5% of the company’s equity, as reported in its latest financial statement. Revenue from this project will contribute to the company’s financial results for FY2025, spanning October 2025 to September 2026.

This development underscores Synektik S.A.'s position as a leader in advanced medical technologies, particularly in robotic surgery, aligning with its business focus on distributing cutting-edge systems like the da Vinci platform and providing comprehensive service solutions.

Synektik S.A. Secures Contract for da Vinci Surgical System with Szpitale Pomorskie

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with Szpitale Pomorskie Sp. z o.o. for the sale, delivery, installation, and commissioning of the da Vinci robotic surgical system. The system, designed for minimally invasive surgeries, will be installed at the Specialist Hospital F. Ceynowy in Wejherowo. The contract also includes additional equipment, staff training, and a 36-month warranty with service support. The deal, valued at PLN 9,251,585.51 net, was awarded through a public procurement process and is expected to be fulfilled within 60 days of signing.

The agreement is considered a key milestone for Synektik S.A., as its value represents 5% of the company’s equity, as reported in its latest financial statement. Revenue from this contract will contribute to the company’s financial results for FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This contract aligns with Synektik S.A.'s core business focus on distributing advanced medical technologies, including the da Vinci surgical system, and reinforces its position as a leader in robotic surgery solutions in Poland.

Synektik S.A. Secures Major Contracts for Robotic Surgery and Cytostatic Drug Preparation Systems

Synektik S.A., a leading Polish medical technology company, has announced the signing of significant contracts with the Provincial Integrated Hospital in Elbląg. The agreements, valued at a net total of PLN 15,492,111.11, involve the delivery, installation, and commissioning of the da Vinci robotic surgery system and the APOTECAchemo robotic system for cytostatic drug preparation. The contracts also include staff training and comprehensive service support during the warranty period.

The procurement was conducted through an open tender process and will be financed by the National Recovery and Resilience Plan. The da Vinci system is expected to be delivered within 12 weeks, while the APOTECA system will be delivered within 20 weeks. The warranty periods are set at 84 months for the da Vinci system and 60 months for the APOTECA system, starting from the signing of final acceptance protocols. The revenue from these contracts will contribute to Synektik's financial results for FY2025, spanning October 2025 to September 2026.

The contracts are deemed significant as their combined value exceeds 5% of Synektik Group's equity, as reported in the latest financial statement, meeting the company's internal reporting standards.

Relevance: This development aligns with Synektik S.A.'s core business focus on providing advanced medical technologies, including robotic surgery systems, and reinforces its position as a key player in the Polish healthcare technology market.

Da Vinci 5: Revolutionizing Robotic Surgery with Advanced Innovations

The fifth-generation da Vinci surgical robot introduces 150 groundbreaking innovations, significantly enhancing precision, ergonomics, and operator control. Key advancements include a more powerful computational system, smoother arm movements, and a redesigned console offering high-resolution 3D imaging and personalized settings. A major breakthrough is the integration of Force Feedback technology, enabling surgeons to "feel" tissue resistance, improving safety and precision during procedures. These enhancements reduce surgery times by 15-20%, minimize complications, and lower healthcare costs by shortening patient recovery periods and hospital stays.

Da Vinci 5 is also future-ready, designed for integration with artificial intelligence, real-time data analysis, and augmented reality, paving the way for decision-support systems and remote surgical education. Despite increasing competition from Chinese robotic systems, the da Vinci platform maintains its edge with a robust clinical base, extensive training networks, and proven reliability, ensuring its continued leadership in robotic surgery.

This article is relevant to Synektik S.A. as the company is the exclusive distributor of da Vinci systems in Poland, aligning with its focus on delivering cutting-edge medical technologies and solutions to healthcare providers.

Polish Medical Supply System Shows Strengths but Requires Updates and Better Coordination

The Polish medical supply system for individually prescribed medical devices has been recognized as efficient, stable, and patient-friendly, but experts highlight the need for regular updates and improved coordination among public institutions. A report by POLMED and INNOWO titled “Medical Devices Issued on Prescription – The Polish System Compared to Neighboring Countries in the Context of Socio-Health Challenges” provides a comprehensive analysis of the system's financing and functionality.

In 2023, Poland issued nearly 413 million medical devices on prescription, ranging from incontinence pads and ostomy bags to wheelchairs, hearing aids, orthoses, and prosthetics. Public funding for these devices amounted to PLN 2.67 billion, averaging PLN 70.9 per capita—the lowest in Central Europe. Despite lower spending, Poland’s flexible financing model ensures strong health outcomes and faster access to innovative technologies compared to neighboring countries. This model allows patients to co-decide on product selection and adapt to market changes, making it resilient to economic shocks such as rising costs of raw materials and transportation.

However, challenges remain, including the aging population, outdated product lists, and fragmented funding sources (NFZ and PFRON). The report recommends regular updates to the product list, indexed funding limits, and streamlined coordination of funding sources. It also suggests involving national consultants, clinicians, patient groups, and industry representatives in the review process, with updates occurring at least every two years. Additionally, transparent procedures for introducing new product categories and adequate vacatio legis periods for regulatory changes are proposed.

Experts emphasize the importance of adapting the system to demographic shifts, technological advancements, and economic realities to ensure better access to modern medical devices and improved patient care.

Relevance to Synektik S.A.: The article highlights the importance of innovation and efficient distribution systems in the medical device sector, aligning with Synektik S.A.'s role as a leading distributor of advanced medical technologies and solutions in Poland.

Synektik S.A. Secures Major Contract for da Vinci Surgical System Supplies

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the State Medical Institute of the Ministry of Internal Affairs and Administration in Warsaw. The contract, valued at a maximum net amount of PLN 9,851,541.97, involves the supply of consumables for the da Vinci robotic surgical system used in minimally invasive procedures. The agreement, awarded through an open tender process, will span 12 months and adheres to standard contractual practices for such arrangements.

The deal is considered crucial by Synektik's management as its value exceeds 5% of the Group's equity reported in the latest financial statement, marking it as a material transaction under the company's internal reporting standards. Revenue from this contract is expected to positively impact Synektik's financial results for fiscal years 2025 and 2026.

Relevance: This agreement underscores Synektik's leadership in distributing advanced medical technologies, including the da Vinci surgical system, aligning with its core business model and strengthening its market position in Poland.

Synektik Introduces Revolutionary da Vinci 5 Surgical System to Poland

Synektik S.A., the exclusive distributor of Intuitive Surgical's da Vinci systems in Poland, has unveiled the fifth-generation da Vinci 5 surgical robot, marking a significant milestone in robotic-assisted surgery. This cutting-edge platform, equipped with over 150 technical innovations and enhanced computational power, enables surgeons to perform minimally invasive procedures with unprecedented precision, real-time data analysis, and seamless collaboration. The system integrates advanced features such as Force Feedback technology, immersive 3D visualization, and automated functionalities, ensuring greater autonomy and efficiency for surgeons.

Since 2018, over 33,000 procedures have been performed in Poland using da Vinci systems, with 73 robots currently operational across the country. Synektik has trained more than 300 operators and numerous surgical teams, solidifying Poland's position as a regional leader in robotic surgery. The da Vinci 5 system further enhances surgical workflows by integrating multiple technologies into a single platform, reducing the need for additional personnel and simplifying operations. Its applications span various specialties, including urology, gynecology, general surgery, and thoracic surgery, supporting over 200 types of procedures.

Synektik's comprehensive approach to implementing robotic surgery includes international certification training, technical support, and ongoing expertise, ensuring the successful adoption of this transformative technology. The introduction of da Vinci 5 underscores the company's commitment to advancing healthcare innovation and improving patient outcomes.

Relevance to Synektik S.A.: This article highlights Synektik's pivotal role in bringing advanced robotic surgical systems to Poland, aligning with its business model of distributing cutting-edge medical technologies and supporting healthcare innovation.

Shurui: A Revolutionary Surgical Robot Challenging Market Leaders

Beijing Surgerii Robotics Company Limited has unveiled Shurui, a groundbreaking surgical robot featuring a dual-continuum mechanism made of flexible nitinol rods, enabling multi-directional bending of instruments. The system supports multi-port, single-port, and hybrid procedures, making it the first of its kind to offer such versatility. Shurui has received CE certification for adult and pediatric procedures in urology, gynecology, general surgery, and thoracic surgery, positioning it as a competitive alternative to Intuitive Surgical's da Vinci systems.

Priced at approximately €2.28 million, Shurui is slightly cheaper than the da Vinci SinglePort (€2.77 million) but more expensive than other Chinese multi-port systems. The robot has already performed over 2,000 surgeries across 70 hospitals in China and 10 European centers, with plans for further expansion in Europe and potential approval in the U.S. Its inclusion in IRCAD's training program in Strasbourg highlights its growing prominence in the global surgical robotics market.

Shurui's innovative design includes manipulators inspired by snake anatomy, offering unmatched dexterity in confined spaces. The system's smaller port diameter (25–26 mm) addresses limitations of da Vinci SP in thoracic surgery, while its pediatric certification provides a competitive edge. Additionally, Shurui has demonstrated capabilities in remote surgeries, showcasing its reliability and precision in telemedicine applications.

Comparative studies have shown Shurui's performance to be on par with da Vinci SP in prostatectomy outcomes, while its advanced features, such as reduced port size and hybrid procedure support, make it a strong contender in the surgical robotics market.

Relevance to Synektik S.A.: The emergence of Shurui highlights increasing competition in the surgical robotics market, directly impacting Synektik S.A., the exclusive distributor of da Vinci systems in Poland. Understanding advancements like Shurui is crucial for Synektik to maintain its market position and adapt to evolving technologies.

Polish Parliament Approves Centralized Hospital Resource Monitoring System

The Polish Parliament has passed a law to establish the Central System for Monitoring Hospital Resources, known as the Provider Potential Registry (EPS). The system, developed by the Ministry of Health, will enable real-time tracking of hospital resources, including beds, medical staff, essential medical supplies, protective equipment, medical gases, and blood. The initiative aims to enhance pre-hospital care by reducing patient rejections at emergency departments and minimizing unnecessary patient transfers between hospitals. Additionally, the system will improve resource management during crises such as pandemics, natural disasters, or military conflicts. EPS will automate data collection directly from hospital IT systems, ensuring efficient reporting and enabling better decision-making in critical situations. The law also phases out COVID-19-specific data reporting requirements, which were introduced during the pandemic but never fully implemented.

Relevance to Synektik S.A.: The implementation of EPS aligns with Synektik S.A.'s focus on advanced IT solutions for healthcare, such as its PACS imaging systems and Zbadani.pl platform, highlighting potential opportunities for the company to contribute to the system's technological infrastructure.

Synektik Secures Medical Equipment Orders Worth 145 Million PLN in Q4 FY 2024

Synektik S.A., a leading Polish medical technology company, has announced a significant increase in orders for medical equipment in the fourth quarter of the fiscal year 2024. The company secured contracts worth approximately 145 million PLN, marking a substantial growth compared to the 82.7 million PLN in orders obtained during the same period last year. This achievement underscores Synektik's expanding presence in the medical equipment market and its ability to meet growing demand for advanced healthcare solutions.

The relevance of this development lies in Synektik's core business model, which focuses on the distribution of cutting-edge medical equipment and IT solutions for healthcare, aligning with its strategic goals and market leadership in Poland.

Healthcare Spending in Poland Reaches 243.8 Billion PLN in 2023

According to data released by the Central Statistical Office (GUS) in the Monitor Polski, Poland's total healthcare spending in 2023 amounted to 243.8 billion PLN, marking a 24% increase compared to 2022's expenditure of 196.2 billion PLN. Public spending accounted for 189.1 billion PLN, with 162.4 billion PLN derived from mandatory health insurance systems and 26.8 billion PLN from government and local administration budgets. Private spending reached 54.7 billion PLN, including 38.6 billion PLN in direct household expenses and 16 billion PLN in other private expenditures.

This significant rise in healthcare investment highlights the growing demand for advanced medical technologies and services, aligning with Synektik S.A.'s focus on providing cutting-edge medical equipment, IT solutions, and radioisotopes for diagnostic imaging.

Synektik S.A. Reports Significant Growth in Medical Equipment Orders for FY 2024

Synektik S.A., a leading Polish medical technology company, has announced a substantial increase in orders within its medical equipment, IT solutions, and services segment. The company secured approximately 391 million PLN in orders for the 2024 financial year, compared to 360 million PLN in 2023. Notably, orders in Q4 2024 reached 145 million PLN, nearly doubling the 82.7 million PLN recorded in Q4 2023.

As of September 30, 2025, the backlog of orders awaiting fulfillment stood at 75.9 million PLN, a significant rise from 36.1 million PLN a year earlier. Additionally, the value of active offers at the end of the period increased to 198.7 million PLN, up from 141.5 million PLN in 2024. These figures are preliminary estimates and will be confirmed in the company’s interim financial report for the period ending September 30, 2025.

The growth in orders highlights Synektik’s strong market position and its ability to meet increasing demand for advanced medical technologies, including robotic surgical systems and diagnostic imaging solutions.

Relevance: This development underscores Synektik S.A.'s leadership in the medical technology sector, aligning with its business model of providing cutting-edge medical equipment and IT solutions to healthcare institutions.

Milickie Centrum Medyczne Advances Orthopedic Surgery with Robotic System Velys

Milickie Centrum Medyczne Advances Orthopedic Surgery with Robotic System Velys

Izabela Laber-Napora, Head of the Rehabilitation Department, emphasized the importance of integrated care, noting that patients are transferred directly to rehabilitation within the same facility, ensuring faster recovery. Dr. Zbigniew J. Król, CEO of the hospital, described the investment in Velys as part of a broader strategy to position the hospital as a modern and patient-friendly healthcare center in the Dolina Baryczy region.

Milickie Centrum Medyczne is the third hospital in Poland to adopt the Velys system, following the Clinical Hospital of the Medical University of Łódź. The robotic system, developed by Johnson & Johnson, assists surgeons by analyzing patient anatomy in real-time and optimizing implant placement. Across Poland, over 20 hospitals utilize robotic systems for joint replacement surgeries, including Velys, Cori (Smith & Nephew), Rosa (Zimmer Biomet), Mako (Stryker), and OmniBotics. Some facilities have also expanded robotic applications to hip replacements.

Relevance to Synektik S.A.: This article highlights the growing adoption of robotic systems in Polish healthcare, a market where Synektik S.A. plays a key role as the exclusive distributor of the da Vinci surgical robot and a leader in advanced medical technologies.

Expansion of PET/CT Indications in Poland Set for January 2026

Starting January 2026, Poland will implement expanded indications for PET/CT imaging, enabling earlier detection and more effective treatment for a broader range of patients. The updated guidelines, outlined in a draft regulation by the President of the National Health Fund, include approximately 20 clinical scenarios eligible for public funding. This marks a significant milestone for nuclear medicine, as advocated by the Polish Society of Nuclear Medicine and other medical experts.

Key advancements include the introduction of PSMA-based radiopharmaceuticals for prostate cancer diagnostics, which outperform traditional fluorocholine methods by detecting cancer at lower PSA levels. Additionally, PET/CT imaging will now be available for neuroendocrine tumors, cervical and endometrial cancers, and non-cancerous conditions like parathyroid adenomas. These updates align Poland with European standards, enhancing diagnostic precision and therapeutic outcomes.

Experts emphasize the transformative impact of these changes, including improved patient prognoses, reduced healthcare costs, and better alignment with modern oncological practices. The expanded indications will also facilitate the use of cutting-edge radiopharmaceuticals and imaging techniques, addressing longstanding gaps in Poland's diagnostic capabilities.

Relevance to Synektik S.A.: As Poland's leading producer and supplier of radiopharmaceuticals, Synektik S.A. stands to benefit significantly from the increased demand for advanced PET/CT imaging solutions, reinforcing its position in the medical technology market.

Synektik Introduces Cutting-Edge Robotic Surgery Systems to Polish Market

Synektik S.A., a leading Polish medical technology company, has expanded its portfolio with the introduction of the latest generation da Vinci 5 robotic surgery system and the single-port da Vinci SP model. The company also launched the Ion endoluminal system for advanced pulmonary bronchoscopy diagnostics. These innovations mark a significant step in enhancing precision and efficiency in minimally invasive procedures.

The da Vinci 5 system, designed with machine learning capabilities and advanced AI algorithms, offers enhanced computational power and introduces haptic feedback for improved surgical precision. Priced at approximately 13 million PLN, it is 30% more expensive than its predecessor, the da Vinci Xi. The single-port da Vinci SP, priced at 12 million PLN, enables surgeries through a single incision, making it ideal for specialized procedures such as radical prostatectomy and head-and-neck surgeries.

Synektik also unveiled the Ion system, priced at 6 million PLN, which provides unparalleled accuracy in lung biopsies. With features like 180-degree maneuverability, fiber-optic construction, and advanced path-planning capabilities, Ion significantly reduces diagnostic time for lung cancer. While no Polish hospitals currently use Ion, its adoption is growing globally, with over 900 units operational in the U.S.

Synektik now manages 77 da Vinci robots in Poland, with projections of over 20,000 robotic surgeries in 2025. The company has trained more than 300 Polish surgeons and plans to open a training center in Warsaw, complementing its existing facility in Prague. Globally, Intuitive Surgical deployed 1,790 new robots in 2024, with a growing trend toward leasing and shared-use models. In total, 2.68 million surgeries were performed using da Vinci systems last year, underscoring their transformative impact on healthcare.

“2025 marks the 30th anniversary of robotic surgery development by Intuitive Surgical, a technology aimed at improving patient outcomes and expanding access to minimally invasive treatments,” said Cezary Kozanecki, founder and CEO of Synektik.

Relevance: This article highlights Synektik's strategic role in introducing advanced robotic systems to Poland, aligning with its business model of distributing cutting-edge medical technologies and supporting healthcare innovation.

Synektik S.A. Appoints Tomasz Wróbel as New Board Member to Drive Operational Transformation

Synektik S.A., a leading Polish medical technology company, has announced the appointment of Tomasz Wróbel as a Member of the Management Board, effective October 1, 2025. The decision was made by the Supervisory Board on September 22, 2025. Wróbel will serve as Chief Operating Officer, focusing on the standardization, integration, and digital transformation of internal processes.

According to official statements, Wróbel does not engage in any competitive activities or hold positions in competing entities. Additionally, he is not listed in the National Debtors Register. His professional background and qualifications are detailed in an accompanying document.

This appointment aligns with Synektik S.A.'s strategic focus on innovation and operational excellence, supporting its leadership in medical technologies, including robotic surgery systems and radiopharmaceuticals.

Synektik S.A. Secures Major Contract for Robotic Surgery System Installation in Zamość Hospital

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the Independent Public Provincial Hospital named after Pope John Paul II in Zamość. The contract involves the delivery, installation, and commissioning of the da Vinci robotic surgery system, alongside adaptation and modernization of the hospital's operating block. Additionally, the agreement includes personnel training and service support during the 36-month warranty period.

The project, valued at PLN 19,131,798.99 net, was awarded through a public procurement process and will be financed by the National Recovery and Resilience Plan. The robotic system is expected to be delivered within eight months of the contract signing. The revenue generated from this project will contribute to Synektik's financial results for the fiscal year 2025-2026.

This contract is deemed significant by Synektik's management as its value exceeds 5% of the company's equity, as reported in its latest financial statement. The agreement aligns with Synektik's strategic focus on providing cutting-edge medical technologies and services to healthcare institutions.

Relevance: This development underscores Synektik's leadership in distributing advanced robotic surgery systems and highlights its commitment to expanding its footprint in Poland's healthcare sector.